tolbutamide has been researched along with Diabetes, Gestational in 6 studies
Tolbutamide: A sulphonylurea hypoglycemic agent with actions and uses similar to those of CHLORPROPAMIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290)
tolbutamide : An N-sulfonylurea that consists of 1-butylurea having a tosyl group attached at the 3-position.
Diabetes, Gestational: Diabetes mellitus induced by PREGNANCY but resolved at the end of pregnancy. It does not include previously diagnosed diabetics who become pregnant (PREGNANCY IN DIABETICS). Gestational diabetes usually develops in late pregnancy when insulin antagonistic hormones peaks leading to INSULIN RESISTANCE; GLUCOSE INTOLERANCE; and HYPERGLYCEMIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Oral glucose tolerance tests (OGTTs) and frequently sampled intravenous glucose tolerance tests (FSIGTs) were conducted on Latino women with impaired glucose tolerance and a history of gestational diabetes before and after 12 weeks of treatment with 400 mg/day troglitazone (n = 13) or placebo (n = 12)." | 5.09 | Response of pancreatic beta-cells to improved insulin sensitivity in women at high risk for type 2 diabetes. ( Azen, SP; Berkowitz, K; Buchanan, TA; Goico, J; Kjos, SL; Marroquin, A; Ochoa, C; Peters, RK; Xiang, AH, 2000) |
| "We conducted a randomized placebo-controlled study to determine the effects of the thiazolidinedione compound troglitazone on whole-body insulin sensitivity (SI), pancreatic beta-cell function, and glucose tolerance in 42 Latino women with impaired glucose tolerance (IGT) and a history of gestational diabetes mellitus (GDM), characteristics that carry an 80% risk of developing NIDDM within 5 years." | 5.08 | Effect of troglitazone on insulin sensitivity and pancreatic beta-cell function in women at high risk for NIDDM. ( Azen, S; Berkowitz, K; Buchanan, TA; Dunn, ME; Goico, J; Kjos, SL; Marroquin, A; Peters, R; Xiang, A, 1996) |
| "The prevalence of pre-eclampsia was significantly increased in the group of women treated with metformin compared to women treated with sulphonylurea or insulin (32 vs." | 3.70 | Oral hypoglycaemic agents in 118 diabetic pregnancies. ( Damm, P; Hellmuth, E; Mølsted-Pedersen, L, 2000) |
| "So far, gestational diabetes treated with tolbutamide has never been associated with severe hypoglycaemia in the newborn when the mother's diabetes was well controlled." | 1.30 | Prolonged elimination of tolbutamide in a premature newborn with hyperinsulinaemic hypoglycaemia. ( Christesen, HB; Melander, A, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, J | 1 |
| Martis, R | 1 |
| Hughes, B | 1 |
| Rowan, J | 1 |
| Crowther, CA | 1 |
| Berkowitz, K | 2 |
| Peters, R | 1 |
| Kjos, SL | 2 |
| Goico, J | 2 |
| Marroquin, A | 2 |
| Dunn, ME | 1 |
| Xiang, A | 1 |
| Azen, S | 1 |
| Buchanan, TA | 2 |
| Fanelli, CG | 1 |
| Bolli, GB | 1 |
| Christesen, HB | 1 |
| Melander, A | 1 |
| Xiang, AH | 1 |
| Peters, RK | 1 |
| Ochoa, C | 1 |
| Azen, SP | 1 |
| Hellmuth, E | 1 |
| Damm, P | 1 |
| Mølsted-Pedersen, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Gain on Closed-Loop Insulin[NCT02065895] | 8 participants (Actual) | Interventional | 2013-12-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Glucose Area Under the Curve (AUC) Breakfast defines the total exposure to glucose during breakfast. Breakfast is typically considered the most difficult meal to control; low AUC is desirable.This outcome measure was analyzed for each of the three calibration error values (high error, no error and low error). (NCT02065895)
Timeframe: On day #1, day #2 and day #3 (each day could be 24 hours to 7 days apart from prior one, and completed within 6 week period) 8:00 AM to 2:00 PM on day following admission, with samples obtained every 10-15 minutes, for each sequence of calibration errors
| Intervention | mmol/l/min (Mean) |
|---|---|
| HIGH Error | 66.8 |
| NO Error | 48.8 |
| LOW Error | 37.4 |
Night-time in target range 5.0-8.33, following the 3 hour controller initialization period blood glucose remained at or near target. (NCT02065895)
Timeframe: On day #1, day #2 and day #3 (each day could be 24 hours to 7 days apart from prior one, and completed within 6 week period) 12:00 AM to 6:00 AM on day following admission, with samples obtained every 10-15 minutes, for each sequence of calibration errors
| Intervention | percentage of time in target range (Median) |
|---|---|
| HIGH Error | 88 |
| NO Errror | 100 |
| LOW Error | 80 |
Highest and lowest glucose concentrations obtained during breakfast meal. (NCT02065895)
Timeframe: On day #1, day #2 and day #3 (each day could be 24 hours to 7 days apart from prior one, and completed within 6 week period) 8:00 AM to 12:00 PM on day following admission, with samples obtained every 10-15 minutes, for each sequence of calibration errors
| Intervention | mmol/l (Mean) | |
|---|---|---|
| Peak glucose concentration | Nadir glucose concentration | |
| Gain Decreased and Target Increased | 11.3 | 6.6 |
| Gain Increased and Target Decreased | 13.3 | 4.5 |
| Nadir Mean | 11.8 | 4.8 |
1 review available for tolbutamide and Diabetes, Gestational
| Article | Year |
|---|---|
Oral anti-diabetic pharmacological therapies for the treatment of women with gestational diabetes.
Topics: Acarbose; Administration, Oral; Diabetes, Gestational; Female; Glyburide; Humans; Hypoglycemia; Hypo | 2017 |
2 trials available for tolbutamide and Diabetes, Gestational
| Article | Year |
|---|---|
Effect of troglitazone on insulin sensitivity and pancreatic beta-cell function in women at high risk for NIDDM.
Topics: Adult; Blood Glucose; Blood Pressure; Body Mass Index; California; Cholesterol, HDL; Cholesterol, LD | 1996 |
Response of pancreatic beta-cells to improved insulin sensitivity in women at high risk for type 2 diabetes.
Topics: Adult; Chromans; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Glucose; Glucose Intolera | 2000 |
3 other studies available for tolbutamide and Diabetes, Gestational
| Article | Year |
|---|---|
Sulphonylureas and pregnancy.
Topics: Diabetes, Gestational; Female; Half-Life; Humans; Hypoglycemic Agents; Maternal-Fetal Exchange; Preg | 1998 |
Prolonged elimination of tolbutamide in a premature newborn with hyperinsulinaemic hypoglycaemia.
Topics: Adult; Diabetes, Gestational; Female; Half-Life; Humans; Hyperinsulinism; Hypoglycemia; Hypoglycemic | 1998 |
Oral hypoglycaemic agents in 118 diabetic pregnancies.
Topics: Abruptio Placentae; Adult; Birth Weight; Cesarean Section; Cohort Studies; Diabetes Mellitus, Type 2 | 2000 |